Loading...
Market
Will major US health insurance providers cover Guardant Health's Shield blood test by May 31, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Insurance company press releases, healthcare policy updates, or official Guardant Health announcements
Story
FDA Approves Guardant Health's Shield Blood Test for Colorectal Cancer Screening
Aug 7, 2024, 12:11 PM
The US FDA has approved Guardant Health's Shield blood test as the first blood test for primary screening of colorectal cancer (CRC) in adults aged 45 and above at average risk. This approval marks a significant advancement in non-invasive cancer screening options. Additionally, the utility of Guardant Reveal, another liquid biopsy test by Guardant Health, has been validated in the COSMOS study published in Clinical Cancer Research. The study confirms the test's effectiveness in predicting recurrence in colorectal cancer, particularly in Stage II and higher cases.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Widely covered • 25%
Partially covered • 25%
Rarely covered • 25%
Not covered • 25%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Below $100 million • 25%
$100 million - $200 million • 25%
$200 million - $300 million • 25%
Above $300 million • 25%
Yes • 50%
No • 50%
